Nav: Home

Virus-based therapy targets a pediatric eye cancer

January 23, 2019

A cancer-killing, virus-based therapy showed promising effects against retinoblastoma - a tumor of the retina that affects mainly children - in mouse models and a pilot clinical trial. Although further work is needed, the therapy lays the groundwork for new treatment options for the cancer, which is currently treated with disfiguring surgery. Researchers estimate that retinoblastoma causes 8,000 cases each year, a figure that represents 11% of all cancers in children under the age of one. Most cases result from inactivation of the gene RB1, which normally plays a critical role as a tumor suppressor. Chemotherapy is the standard-of-care for retinoblastoma, but intensive rounds of such drugs can damage the retina and cause long-term vision problems. In some cases, surgery is needed to remove the eye entirely - an invasive procedure called enucleation that results in loss of vision. Here, Guillem Pascual-Pasto and colleagues investigated an alternative treatment for retinoblastoma named VCN-01, which harnesses a virus that infects and kills cancer cells harboring a dysfunctional RB1 pathway. The treatment was safe in juvenile rabbit models, and injections of the virus into the eyes of mice with retinoblastoma (equivalent to a feasible dosage for human children) curtailed tumor growth, prevented metastasis, and extended the time to enucleation compared to chemotherapy. Importantly, the authors administered VCN-01 to two pediatric patients with retinoblastoma and observed the virus successfully replicated in tumor cells and did not cause systemic inflammation. Taken together, the findings warrant further development of VCN-01 as a potential treatment for patients with retinoblastoma and RB1 inactivation, Pascual-Pasto et al. say.
-end-


American Association for the Advancement of Science

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".